Xeljanz (tofacitinib citrate) - Articles and news items

Positive top-line results for tofacitinib citrate in active psoriatic arthritis

Industry news / 8 June 2016 / Victoria White, Digital Content Producer

The OPAL Beyond study met its primary efficacy endpoints demonstrating a statistically significant improvement with tofacitinib 5 mg BID and 10 mg BID…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+